D.E. Shaw & Co’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

D.E. Shaw & Co’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-71,236	Closed	-$2.01K	–	5004
2024 Q2	$2.01K	Hold	71,236	–	–	﹤0.01%	4402
2024 Q1	$6.41K	Hold	71,236	–	–	﹤0.01%	4201
2023 Q4	$7.5K	Hold	71,236	–	–	﹤0.01%	4148
2023 Q3	$16K	Hold	71,236	–	–	﹤0.01%	4015
2023 Q2	$18.7K	Hold	71,236	–	–	﹤0.01%	3978
2023 Q1	$12.8K	Hold	71,236	–	–	﹤0.01%	4203
2022 Q4	$14.2K	Hold	71,236	–	–	﹤0.01%	4568
2022 Q3	$51K	Hold	71,236	–	–	﹤0.01%	4689
2022 Q2	$38K	Hold	71,236	–	–	﹤0.01%	4890
2022 Q1	$63K	Hold	71,236	–	–	﹤0.01%	5090
2021 Q4	$160K	Sell	71,236 -86,275	-55%	-$279K	﹤0.01%	4948
2021 Q3	$534K	Buy	+157,511	New	+$561K	﹤0.01%	4044

Other funds holding DNA.WS

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $190M AUM 36.38% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

D.E. Shaw & Co's DNA.WS Position: Q3 2024 in Review

D.E. Shaw & Co sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q3 2024, closing a stake of 71,236 shares — an estimated $2.01K sold.

D.E. Shaw & Co first reported a position in DNA.WS in Q3 2021 and held it in 12 quarters. The position peaked at $534K in Q3 2021. 5 funds tracked by Wall St. Rank hold DNA.WS as of Q3 2024.

D.E. Shaw & Co reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q3 2024 after selling out during the quarter.
D.E. Shaw & Co sold 71,236 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q3 2024, an estimated $2.01K.
D.E. Shaw & Co first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 12 quarters.
D.E. Shaw & Co's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $534K in Q3 2021.
5 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.